New hope for kids with MS: major trial tests promising treatments
NCT ID NCT07483632
Summary
This study is testing two oral medications, diroximel fumarate (DRF) and dimethyl fumarate (DMF), in children and teenagers with relapsing forms of multiple sclerosis (MS). The main goals are to see how safe these drugs are for young people and to compare how well they control MS relapses and brain lesions against another established MS drug, fingolimod. About 185 participants will take part in this two-part study, which includes an initial 96-week treatment period and an optional 96-week extension to look at long-term effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING FORMS OF MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.